Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value
$1.71+0.09 (+5.56%)
Close on Nov 13, 2026Market cap $14.10MP/E –Yield –
Lipocine ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lipocine's ebitda for the twelve months ending Sep 30, 2026 was -$10.02M. For fiscal 2025 it was -$10.31M. The highest annual figure on record is $3.92M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.31M | – |
| FY2024 | Dec 31, 2024 | -$1.11M | – |
| FY2023 | Dec 31, 2023 | -$17.90M | – |
| FY2022 | Dec 31, 2022 | -$12.11M | -484.9% |
| FY2021 | Dec 31, 2021 | $3.15M | – |
| FY2020 | Dec 31, 2020 | -$17.99M | – |
| FY2019 | Dec 31, 2019 | -$12.88M | – |
| FY2018 | Dec 31, 2018 | -$11.31M | – |
| FY2017 | Dec 31, 2017 | -$21.19M | – |
| FY2016 | Dec 31, 2016 | -$19.15M | – |
| FY2015 | Dec 31, 2015 | -$18.36M | – |
| FY2014 | Dec 31, 2014 | -$20.47M | – |
| FY2013 | Dec 31, 2013 | -$10.66M | -372.0% |
| FY2012 | Dec 31, 2012 | $3.92M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$853.88K | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.83M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.50M | -260.2% |
| Q3 FY2025 | Sep 30, 2025 | -$3.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.07M | -164.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.28M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.60M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.97M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.35M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.16M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.76M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.90M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.01M | – |
See a number that looks wrong?